

RESEARCH

Open Access



Can computed tomography-based radiomics potentially discriminate between anterior mediastinal cysts and type B1 and B2 thymomas?

Lulu Liu^{1,2,3}, Fangxiao Lu^{1,2,3}, Peipei Pang⁴ and Guoliang Shao^{1,2,3*} 

*Correspondence:

449031795@qq.com

³ Department of Radiology, Zhejiang Cancer Hospital, No. 1 Banshan Street, Gongshu District, Hangzhou 321022, Zhejiang, People's Republic of China

Full list of author information is available at the end of the article

Abstract

Background: Anterior mediastinal cysts (AMC) are often misdiagnosed as thymomas and undergo surgical resection, which caused unnecessary treatment and medical resource waste. The purpose of this study is to explore potential possibility of computed tomography (CT)-based radiomics for the diagnosis of AMC and type B1 and B2 thymomas.

Methods: A group of 188 patients with pathologically confirmed AMC (106 cases misdiagnosed as thymomas in CT) and thymomas (82 cases) and underwent routine chest CT from January 2010 to December 2018 were retrospectively analyzed. The lesions were manually delineated using ITK-SNAP software, and radiomics features were performed using the artificial intelligence kit (AK) software. A total of 180 tumour texture features were extracted from enhanced CT and unenhanced CT, respectively. The general test, correlation analysis, and LASSO were used to features selection and then the radiomics signature (radscore) was obtained. The combined model including radscore and independent clinical factors was developed. The model performances were evaluated on discrimination, calibration curve.

Results: Two radscore models were constructed from the unenhanced and enhanced phases based on the selected four and three features, respectively. The AUC, sensitivity, and specificity of the enhanced radscore model were 0.928, 89.3%, and 83.8% in the training dataset and 0.899, 84.6%, and 87.5% in the test dataset (higher than the unenhanced radscore model). The combined model of enhanced CT including radiomics features and independent clinical factors yielded an AUC, sensitivity and specificity of 0.941, 82.1%, and 94.6% in the training dataset and 0.938, 92.3%, and 87.5% in the test dataset (higher than the unenhanced combined model and enhanced radscore model).

Conclusions: The study suggested the possibility that the combined model in enhanced CT provided a potential tool to facilitate the differential diagnosis of AMC and type B1 and B2 thymomas.

Keywords: Anterior mediastinal cysts, Thymomas, Radiomics, Enhanced CT



Background

Thymoma is the most common tumour in the anterior mediastinum [1, 2]. According to the 2015 World Health Organization (WHO) classification of thymic epithelial tumours, thymomas are no longer classified as benign tumours. Except for micronodular thymoma with lymphoid stroma and micro-thymomas are benign, all other types of thymoma are considered malignant tumours [3]. Thus, when the mediastinal mass is suspected to be a thymoma, surgical resection is needed [4, 5].

Currently, routine computed tomography (CT) is widely used as a routine method diagnosing lesions in the thymoma and anterior mediastinal cysts (AMC). Type A and AB thymomas have many thymic epithelial cells and are heterogeneous on enhanced CT imaging. Type B3 thymomas and thymic carcinomas may invade the surrounding structures due to their high invasiveness, and most of them can easily be distinguished from cysts preoperatively. Otherwise, type B1 and B2 thymomas comprise many lymphocyte cells and even enhancement on enhanced CT imaging, and thymoma often have a complete capsule, making it difficult to distinguish them from AMC [6–8]. Meanwhile, the CT value of some AMC may be similar to the soft tissue density, due to the influence of mediastinal large blood vessels and the thorax, the CT values of the enhanced mediastinal window are not accurate, and some are even lower than the unenhanced CT values [9, 10], which make the diagnoses mainly based on radiologists' subjective experience. Thus, patients with AMC are often misdiagnosed as thymomas and undergo surgical resection, not only causing unnecessary treatment but also wasting medical resources. In this study, 106 included cases of AMC were all misdiagnosed as thymomas and underwent surgical resection.

Radiomics can extract a high-throughput objective and quantitative image features from CT, magnetic resonance imaging (MRI), or positron emission tomography (PET) to reflect tumour heterogeneity [11–13] and explore the potential relationships between features and pathophysiology to predict clinical outcomes, such as differential diagnosis, classification, distant metastases, survival [14–17]. A few studies discussed the role of quantitative image analysis based on magnetic resonance imaging (MRI) parameters in differentiation anterior mediastinal cysts from other solid masses, which may help to characterize correlation of thymic epithelial tumours with World Health Organization classification and clinical staging [18, 19]; Qualitative CT radiomics analysis were also applied to thymic tumours grading [20]; however, radiomics-based studies of only AMC distinguished from type B1 and B2 thymomas have not been reported. Therefore, this retrospective study attempts to study whether CT radiomics can reflect the heterogeneity between AMC and type B1 and B2 thymoma and to avoid the resection of AMC that are misdiagnosed as thymomas.

Results

Patient characteristics

106 anterior mediastinal cysts patients (all were misdiagnosed as thymomas in CT) and 82 type B1 and B2 thymomas patients were included in the study. A patient pathologically confirmed AMC but was misdiagnosed as thymoma in CT image was shown in Fig. 1.




Fig. 1 A patient pathologically confirmed anterior mediastinal cyst. **a** Round lesion located in the anterior mediastinum; **b** CT value of 50.73 HU in the unenhanced mediastinal window, CT value of 39.15 HU in the enhanced mediastinal window, even lower than the unenhanced CT value; **c** light microscopy of frozen section of a lesion stained, original magnification $\times 100$ showing the ciliated columnar epithelium lining the lesion capsule

Table 1 Characteristics of patients in the training and test datasets

Characteristics	Training dataset (N = 130)			Test dataset (N = 58)		
	AMC (N = 74)	Thymoma (N = 56)	P	AMC (N = 32)	Thymoma (N = 26)	P
Age (years)	54.19 ± 8.05	50.71 ± 9.17	0.110	55.81 ± 9.52	44.62 ± 13.04	0.013
Gender			0.213			0.577
Male	34(45.9%)	18(32.1%)		20 (62.5%)	12 (46.2%)	
Female	40 (54.1%)	38 (67.9%)		12(37.5%)	14 (53.8%)	
Primary site			0.301			0.041
Left	44 (59.5%)	30 (53.6%)		22 (68.7%)	18 (69.2%)	
Right	30 (40.5%)	26 (46.4%)		10 (31.3%)	8 (30.8%)	
Lesion size (cm)	2.72 ± 1.40	3.41 ± 1.26	0.043	2.60 ± 1.34	3.52 ± 1.24	0.069
Unenhanced CT value	33.14 ± 17.59	43.34 ± 9.76	0.004	27.90 ± 17.14	38.06 ± 9.21	0.053
Enhanced CT value	35.26 ± 18.19	67.74 ± 16.34	0.000	34.40 ± 20.04	57.07 ± 16.61	0.003
Change of CT value	2.13 ± 12.45	24.40 ± 12.67	0.000	6.50 ± 14.68	19.01 ± 13.25	0.025
Radscore	- 2.52 ± 2.22	2.30 ± 2.72	0.000	- 2.41 ± 1.77	1.96 ± 2.66	0.000

Bold indicates *p* values below 0.05 were considered significant in both training and test datasets


Continuous variables: represented as mean ± standard deviation (SD); Chi-square test or Fisher's exact test [number and percentage (%)]

CT computed tomography, HU Hounsfield unit, change of CT value enhanced CT value – unenhanced CT value, AMC anterior mediastinal cysts

Detail clinical features in training and test dataset were described in Table 1. The maximum diameter [21] of the tumour was 0.9–7.7 cm, and the average diameter was 3.0 ± 1.4 cm. A statistically significant difference was found in lesion size and unenhanced CT value between AMC and thymomas in the training dataset, but no statistically significant difference in age and primary site ($P > 0.05$). There was a significant difference found in enhanced CT value, change of CT value and radscore in the training and test datasets. Moreover, the radscore was the dominant factor impacting the prediction of the differential diagnosis between AMC and type B1 and B2 thymomas ($P < 0.001$).

Radscore model development and performance evaluation

Among the 180 features of enhanced CT, the correlation based on the heatmap, two main clusters of 188 patients were compared, and a visual association was found, demonstrating the potential discriminative power of these radiomics features (Fig. 2).



After the feature selection, four and three imaging features were finally selected from unenhanced phase and enhanced phase CT, respectively, for the construction of the radscore model. The VIFs of four features in unenhanced CT and three features in enhanced phase CT were all less than ten, which indicated no severity collinearity. The lasso images of the unenhanced and enhanced phases were shown in Fig. 3.

Equation 1 represents the unenhanced phase CT for four radiomics features:

$$\begin{aligned} \text{radscore} = & 0.293 \times \text{Quantile0.025} + 1.306 \times \text{VoxelValueSum} \\ & + 0.356 \times \text{GLCMEntropy_angel0_offset1} - 0.532 \\ & \times \text{HaralickCorrelation_AllDirection_offset1_SD} - 0.278. \end{aligned} \quad (1)$$


Equation 2 represents the enhanced phase CT for three radiomics features:

$$\text{Radscore} = 2.706 \times \text{RMS} + 0.520 \times \text{VoxelValueSum} - 0.951 \times \text{SurfaceVolumeRatio} - 0.447. \quad (2)$$

The AUC, sensitivity, and specificity of the enhanced radscore model were 0.928, 89.3%, and 83.8%, respectively, in the training dataset and 0.899, 84.6%, and 87.5%, respectively, in the test dataset (higher than the unenhanced radscore model) (Table 2). The AUC values were consistent with the results of 1000 times bootstrap analysis in both training and test dataset (mean \pm standard deviation: training dataset: 0.928 ± 0.025 ; test dataset: 0.899 ± 0.039).

Development of combined model and models comparison

Two clinical unenhanced CT value and enhanced CT value were selected from seven clinical features to develop the clinical models by stepwise multivariable analysis using the minimum Akaike information criterion (AIC) as the stop rule. A combined model including radscore, unenhanced CT value and enhanced CT value was constructed. The VIFs of combined models were calculated, the values all were less than ten, which indicated no severity collinearity.



Equation 3 represents the unenhanced phase CT for combined model:

$$\begin{aligned} \text{Combine - model} &= 0.822 \times \text{radscore} + 0.127 \times \text{enhanced CT value} \\ &\quad - 0.074 \times \text{unenhanced CT value} - 3.443. \end{aligned} \tag{3}$$

Equation 4 represents the enhanced phase CT for combined model:

$$\begin{aligned} \text{Combine - model} &= 0.633 \times \text{radscore} + 0.083 \times \text{enhanced CT value} \\ &\quad - 0.053 \times \text{unenhanced CT value} - 2.319. \end{aligned} \tag{4}$$

The performance of clinical models, radscore models, and combined models of the unenhanced and enhanced phases CT were evaluated by ROC (Fig. 4). The AUC, sensitivity, specificity, 95% confidence interval (CI), *P* value, Youden index of the training and test datasets of the unenhanced model and enhanced model were detailedly shown in Table 2. The AUC of combined model was greater than radscore model and

Table 2 Differential diagnostic efficiency between AMC and type B1 and B2 thymomas

	AUC	95% CI	Sensitivity	Specificity	Youden	P value
Radscore model						
Unenhanced CT						
Training dataset	0.823	0.709–0.907	0.757	0.821	0.578	0.000
Test dataset	0.856	0.676–0.958	1	0.769	0.769	0.000
Enhanced CT						
Training dataset	0.928	0.835–0.977	0.893	0.838	0.731	0.000
Test dataset	0.899	0.730–0.979	0.846	0.875	0.721	0.000
Combined model						
Unenhanced CT						
Training dataset	0.933	0.843–0.980	0.893	0.838	0.731	0.000
Test dataset	0.928	0.768–0.991	0.923	0.875	0.798	0.000
Enhanced CT						
Training dataset	0.941	0.853–0.984	0.821	0.946	0.767	0.000
Test dataset	0.938	0.781–0.993	0.923	0.875	0.798	0.000

Bold indicates *p* values below 0.05 were considered significant in both training and test datasets


clinical model in two datasets of enhanced and unenhanced CT, the combined model of enhanced CT was the highest. So, the diagnosis efficiency of enhanced model was better than unenhanced model.

Combined nomogram of the enhanced CT model

A combined nomogram of the enhanced CT was constructed based on radscore, unenhanced CT value, and enhanced CT value. The combined nomogram and calibration curves also indicated good agreement between the nomogram prediction and actual observation in both the training and test datasets (Fig. 5). For the training dataset, a non-significant statistic ($P=0.735$) of the Hosmer–Lemeshow test indicated no significant deviation from an ideal fitting. The AUC value was 0.941 (95% CI 0.853–0.984). For the test dataset, a non-significant statistic ($P=0.602$) and an AUC of 0.938 (95% CI 0.781–0.993) were obtained (Table 2). Using the bootstrap method, the AUC values were consistent with above results in both training and test dataset (mean \pm standard deviation: training dataset: 0.941 ± 0.021 ; test dataset: 0.938 ± 0.033).


Discussion

In this study, a nomogram based on enhanced CT was developed and validated using radiomics method for quantified the probability of the differential diagnosis of anterior mediastinal cysts and type B1 and B2 thymomas. The combined nomogram was constructed by incorporating the radscore and the two clinical features of unenhanced CT value and enhanced CT value. The radscore was calculated from the CT images, which was developed by the selective image features. The combined model of enhanced CT images yielded an optimal AUC in both training and test datasets (training dataset: 0.941, test dataset: 0.938). Invasive procedures such as endoscopic biopsy of the mediastinal mass are dangerous, because these masses are near the heart and mediastinal great



vessels [22, 23]. Thus, a non-invasive biomarker that can be obtained preoperatively to diagnose anterior mediastinal cysts from type B1 and B2 thymomas will be valuable in clinical practice.

For our study, we found that the extracted features of the unenhanced and enhanced CT images were different, and the models had different efficiency. The AUC of the unenhanced radscore model were 0.823 in training dataset and 0.856 in test dataset, respectively, and 0.928 and 0.899 for enhanced radscore model, which were higher than those of the unenhanced radscore model. The AUCs of the training and test datasets of the unenhanced combined model were 0.933 and 0.928, respectively, and the AUCs of the training and test datasets of the enhanced combined model were 0.941 and 0.938, respectively, also higher than those of the unenhanced model. The results suggested that the features of enhanced phase CT imaging can better reflect the internal heterogeneity of AMC than unenhanced phase CT imaging. The AUCs of



the combined model both in the unenhanced and enhanced phases were higher than those of the radscore model, the combined models included not only image features but also unenhanced CT and enhanced CT values of the mediastinal window of clinical features, indicating that the clinical features of the CT value was a very important biomarker for the differential diagnosis between anterior mediastinal cysts and type B1 and B2 thymomas. As the nomogram illustrates, the radscore accounted for most of the proportion compared with the other clinical features, making the radiomics signature as a cardinal biomarker to predict the differential diagnosis of AMC and type B1 and B2 thymomas. The higher the total points of the nomogram are, the more likely type B1 and B2 thymomas are to be diagnosed.

Yasaka et al. [24, 25] studied that the enhanced phase CT could better reflect the internal heterogeneity of anterior mediastinal thymomas and other masses than the unenhanced phase using quantitative computed tomography texture analysis to estimate the histological subtypes of thymic epithelial tumours and differentiation between solid masses and cysts. Only few scholars have conducted relevant research in the radiomics field. Wang et al. [26] obtained the results that the AUCs were 0.829 and 0.860 for the

radiomics signature based on unenhanced and enhanced CT images in differentiating advanced stage thymomas from early stage thymomas, respectively. However, Sui et al. [27] believed that the unenhanced phase could better distinguish high-risk and low-risk thymomas than the enhanced phase, because more texture features were selected from the unenhanced phase than from the enhanced phase, and tumour heterogeneity was better detected in the unenhanced phase, the above studies were similar to our results that the enhanced CT and unenhanced CT radiomics can better differentiating the different stages of thymoma, the enrolled thymomas were confirmed by Masaoka clinical stage and WHO histologic classification. In our study, only AMC distinguished from type B1 and B2 thymomas was enrolled to research, because most of type B3 thymic carcinomas can easily be distinguished from cysts preoperatively by CT manifestations. Otherwise, type B1 and B2 thymomas often have a complete capsule even on enhanced CT imaging, making it difficult to distinguish them from AMC. Through this study, the AUCs of combined model distinguishing AMC distinguished from type B1 and B2 thymomas in enhanced and unenhanced CT were all greater than 0.9 in training and test datasets, the sensitivity and specificity were also greater than 0.8. More sample sizes and multi-center external data will be included to further validate our results.

The seven feature parameters selected in this study reflected the distribution of the image grey value, texture features and spatial differences of VOI [28–30]. The feature parameters extracted from the unenhanced phase were the Quantile0.025 and VoxelValueSum of the histogram texture, the feature parameters extracted from the enhanced phase were the RMS, VoxelValueSum of histogram texture and SurfaceVolumeRatio of formfactor texture. The feature parameters extracted from the unenhanced and enhanced phases both included the VoxelValueSum, also indicating that the tumour size had important contributions for differentiating between AMC and thymomas. The coefficient SurfaceVolumeRatio extracted from the enhanced phase was -0.951 and was negatively correlated with the proportion of thymoma diagnosed, thus indicating a more subglobular mediastinal lesion and a greater likelihood of a thymoma diagnosis, which was consistent with a radiologist's diagnosis by routine imaging [31]. GLCM is defined by the joint probability density of pixels at different positions, reflecting comprehensive information about the direction and amplitude of the imaging grey distribution, mainly reflecting the influence of pixels on spatial dependence and the relationship with the surrounding environment. The feature parameters extracted from the unenhanced phase were GLCMEntropy_angel0_offset1 and HaralickCorrelation_AllDirection_offset1_SD of GLCM texture, which indicated the heterogeneity of the lesion and degrees of complexity and similarity of the greyscale distribution; this features reflect the degree of the difference of the internal details of the lesion from different aspects, the critical factor to distinguish between AMC and thymomas.

Our study still had several limitations. First, the patients were collected from a single institution retrospectively and the number of patients included in our study was also small, the statistical results reflected in our results may be limited, further larger sample size and multi-center are needed to test the proposed model. Second, we cannot explain the selected feature results to clinicians and patients reasonably.

Conclusion

In summary, the combined model based on enhanced CT and clinical factors as a non-invasive biomarker may provide a potential tool to facilitate the differential diagnosis of anterior mediastinal cysts and type B1 and B2 thymomas. With further clinical research, a radscore model may provide complementary diagnostic information and help to avoid unnecessary surgical resection for patients with anterior mediastinal cysts.

Methods

Subjects

This retrospectively study was approved by the ethics committee of the hospital, and the requirement for informed consent was waived.

188 patients with AMC or type B1 and B2 thymomas confirmed by pathology in the department of thoracic oncology at our hospital from January 2010 to December 2018 were collected. The inclusion criteria were as follows: (1) complete routine unenhanced and enhanced chest CT images; (2) round and uniformly dense lesions without infiltration of surrounding tissues. (3) All included AMC misdiagnosed as thymomas and underwent resection. Patients with incomplete CT images were excluded. Finally, 188 patients were included in the study, 84 males and 104 females, mean aged 52 (19–70) years.


Baseline clinical features were derived from our medical records, including age, sex, primary site (left or right), lesion size, unenhanced CT value, enhanced CT value and change of CT value (enhanced CT value minus unenhanced CT value).

Examination methods

Unenhanced and 1-phase enhanced chest CTs were performed using a Siemens Definition Flash 64 row. The scanning sequences were the following parameters: tube voltage 120 kV, tube current 250 mAs, 5-mm section collimation, field of view, 300 mm, matrix, 512×512 , pixel size, 0.68×0.68 mm. 38-s delay scan was for enhanced phase CT scan after the administration of 100 to 120 mL of 300 mg/mL iodinated contrast material (Loversol Injection; Liebel-Flarsheim Canada Inc.) at a 3-mL/s injection rate with a pump injector. All patients were scanned with the same machine using identical scanning parameters to ensure the same imaging parameters.

VOI segmentation and radiomics feature extraction

The chest CT images were obtained from the Picture Archiving and Communication Systems (PACS) database. For both the unenhanced phase and enhanced phase CT



images of the mediastinal window, a 3D volume of interest (VOI) manual segmentation was performed using ITK-SNAP software (Version3.4.0, <http://www.itksnap.org/>) (Fig. 6). When multiple tumours were present, the largest diameter tumour was used to analyse.

We randomly chose 60 unenhanced and enhanced CT images for intraclass correlation coefficient (ICC). The segmentation was performed independently by two experienced radiologists. Intra-observer ICC was computed by comparing two extractions of reader A (10 years of experience in chest CT). Inter-observer ICC was computed by comparing reader A and reader B (15 years of experience in chest CT). When the ICC was greater than 0.75, it was considered good agreement, and the remaining 128 image segmentation was performed by reader A. We then obtained two feature sets (feature set 1 of 188 overall patients were extracted by reader A and feature set 2 of 60 randomly images by reader B). The feature set 1 was used to perform the model training and feature set 2 was used to test the robustness and reproducibility of features from set 1.

Image processing was applied before feature extraction, including image resample to $1 \times 1 \times 1 \text{ mm}^3$ voxel size and image grey normalization to uniform greyscale of 0–255. A total number of 180 image features were extracted for each patient from the enhanced and unenhanced CT images based on VOI by AK software (Artificial Intelligence Kit V3.0.0.R; GE Healthcare). The feature set included histogram features (number=42), grey level co-occurrence matrix (GLCM) features (number=58), grey-level run-length matrix (RLM) features (number=60), formfactor features (number=9) and grey-level size-zone matrix (GLZSM) features (number=11) [32]. These features could characterize intratumour heterogeneity, may contain the underlying genotypes and protein structures [33, 34].

Feature selection and radiomics signature construction

To eliminate the differences in the value scales of extraction features, feature normalization was performed before feature selection, each feature for all patients was normalized with Z scores subtracting the mean value and divided by standard deviation [35].

All the patients were randomly divided into the training ($n=130$) and test ($n=58$) datasets at a ratio of 7:3 [36]. The feature selection and radiomics signature construction was performed in the training dataset. Four steps were used to feature selection. First, the ICC was used to select the robustness and reproducibility features to reduce the manual segmentation among different radiologists [37]. ICC greater than 0.75 indicated a high correlation according to the thumb rule [38]. Second, univariate logistic regression was used to select the independent risk features with $P < 0.05$. Third, correlation analysis was conducted on any two features, when the correlation coefficient was greater than 0.9, excluding one of them. The final step method was least absolute shrinkage and selection operator (LASSO) [39] to further select the most useful features by penalty parameter tuning λ , we chose the optimal λ based on the minimum criteria according to tenfold cross-validation. This method was widely used for the radiomics analysis of high-dimensional features but small medical images.

The selected features were used to construct the radscore model. A radiomics signature (radscore) was then calculated for each patient via a linear combination of selected features that was weighted by their respective coefficients.

Construction and validation of combined model

Univariate logistic regression was used for seven clinical features in the training datasets, including gender, age, primary site, lesion size, unenhanced CT value, enhanced CT value and change of CT value, to select independent clinical predictors. Multivariable logistic regression analysis combining above independent clinical risk factors and radscore was applied to develop combined model for the differential diagnosis between AMC and type B1 and B2 thymomas [40]. To detect the multi-collinearity between variables in the combined model, the variance inflation factor (VIF) was used to perform the collinearity diagnosis with the VIFs > 10 indicating a severity collinearity [41].

The discrimination and calibration curve were used to evaluate the performances of the clinical models, radscore models and combined models (unenhanced and enhanced CT) in the training and test datasets. The discrimination performance was accessed by receiver operating characteristic (ROC) curve and area under the curve (AUC), accuracy, sensitivity and specificity. To estimate the predict error, we further tested the proposed model of enhanced CT using a 1000-iteration bootstrap analysis in both datasets of enhanced CT. For each repetition, a random subset of 50% patients from training or test was selected and the corresponding AUC was calculated [42]. Furthermore, nomogram of the combined model of enhanced CT was constructed. The calibration curve was used to detect the consistency between the predicted and actual AMC probability, which was quantitatively evaluated by Hosmer–Lemeshow test indicating the goodness of model fit when $P > 0.05$ [43].

Statistical analysis

All statistical analysis was executed by R software (version 3.0.1; <http://www.Rproject.org>). Univariate analysis for clinical features was performed using independent sample *t* test or the Mann–Whitney *U* for continues variable and Chi-squared test for categorical variable (sex, primary site). The statistical significance levels were all two-sided, with statistical significance set at 0.05 [44]. Multivariate logistic regression analysis was performed using the “stats” package. Nomogram construction was performed using the “rms” package.

Abbreviations

AMC: Anterior mediastinal cysts; AUC: Area under the curve; AK: Artificial intelligence kit; CT: Computed tomography; CI: Confidence interval; GLCM: Grey-level co-occurrence matrix; GLZSM: Grey-level size-zone matrix; HU: Hounsfield unit; ICC: Intraclass correlation coefficient; LASSO: Least absolute shrinkage and selection operator; PACS: Picture archiving and communication systems; ROC: Receiver operating characteristic; ROI: Region of interest; RLM: Run-length matrix; SD: Standard deviation; WHO: World Health Organization; 3D: Three dimensions.

Acknowledgements

None.

Authors' contributions

LLL and GLS were involved in the study conception and the study design. LLL and FXL implemented the study. LLL and GLS were involved in data management and planning the analysis. LLL and PPP did the analysis. All authors were involved in interpreting the data. LLL and FXL wrote the first draft. All authors read and approved the final manuscript.

Funding

Funding was provided by Zhejiang Major Science and Technology Project (2019C03058), Zhejiang Medicine and Health Science and Technology Program (2019KY324).

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available due to an IRB decision which was made in the interest of ensuring patient confidentiality but are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This retrospective study was approved by the ethics committee of Zhejiang Cancer Hospital, University of Chinese Academy of Sciences; the informed consent requirement was waived.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflict of interest.

Author details

¹ Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, China. ² Department of Radiology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China. ³ Department of Radiology, Zhejiang Cancer Hospital, No. 1 Banshan Street, Gongshu District, Hangzhou 321022, Zhejiang, People's Republic of China. ⁴ Life Sciences, GE Healthcare, Hangzhou 310000, Zhejiang, China.

Received: 14 May 2020 Accepted: 17 November 2020

Published online: 27 November 2020

References

1. Scorsetti M, Leo F, Trama A, et al. Thymoma and thymic carcinomas. *Crit Rev Oncol Hematol*. 2016;3(99):332–50. <https://doi.org/10.1016/j.critrevonc.2016.01.012>.
2. Jamilloux Y, Frih H, Bernard C, et al. Thymoma and autoimmune diseases. *Rev Med Interne*. 2018;39(1):17–26. <https://doi.org/10.1016/j.revmed.2017.03.003>.
3. Travis WD, Brambilla E, Burke AP, et al. World Health Organization classification of tumours: pathology and genetics of tumours lung, pleura, thymoma and heart. Lyon: IARC Press; 2015. p. 187–243.
4. Comacchio GM, Marulli G, Mammanna M, et al. Surgical decision making: thymoma and myasthenia gravis. *Thorac Surg Clin*. 2019;29(2):203–13. <https://doi.org/10.1016/j.thorsurg.2018.12.007>.
5. Burt BM, Nguyen D, Groth SS, et al. Utilization of minimally invasive thymectomy and margin-negative resection for early-stage thymoma. *Ann Thorac Surg*. 2019;108(2):405–11. <https://doi.org/10.1016/j.athoracsur.2019.03.010>.
6. Weissferdt A, Kalhor N, Bishop JA. Thymoma: a clinicopathological correlation of 1470 cases. *Hum Pathol*. 2018;73:7–15. <https://doi.org/10.1016/j.humpath.2017.08.018>.
7. Pfister F, Hussain H, Belharazem D, et al. Vascular architecture as a diagnostic marker for differentiation of World Health Organization thymoma subtypes and thymic carcinoma. *Histopathology*. 2017;70(5):693–703. <https://doi.org/10.1111/his.13114>.
8. Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. *Eur J Cancer*. 2012;48(4):441–6. <https://doi.org/10.1016/j.ejca.2011.11.036>.
9. Chaturvedi A, Gange C, Sahin H, et al. Incremental value of magnetic resonance imaging in further characterizing hypodense mediastinal and paracardiac lesions identified on computed tomography. *J Clin Imaging Sci*. 2018;8:10. https://doi.org/10.4103/jcis.JCIS_63_17.
10. Nam JG, Goo JM, Park CM, et al. Age- and gender-specific disease distribution and the diagnostic accuracy of CT for resected anterior mediastinal lesions. *Thorac Cancer*. 2019;10(6):1378–87. <https://doi.org/10.1111/1759-7714.13081>.
11. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. *Radiology*. 2016;278(2):563–77. <https://doi.org/10.1148/radiol.2015151169>.
12. Verma V, Simone CB 2nd, Krishnan S, et al. The rise of radiomics and implications for oncologic management. *J Natl Cancer Inst*. 2017. <https://doi.org/10.1093/jnci/djx055>.
13. Yuan Y, Ren J, Shi Y, et al. MRI-based radiomic signature as predictive marker for patients with head and neck squamous cell carcinoma. *Eur J Radiol*. 2019;117:193–8. <https://doi.org/10.1016/j.ejrad.2019.06.019>.
14. Parmar C, Leijenaar RT, Grossmann P, et al. Radiomic feature clusters and prognostic signatures specific for lung and head and neck cancer. *Sci Rep*. 2015;5:11044. <https://doi.org/10.1038/srep11044>.
15. Huang YQ, Liang CH, He L, et al. Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. *J Clin Oncol*. 2016;34(18):2157–64. <https://doi.org/10.1200/JCO.2015.65.9128>.
16. Li K, Sun H, Lu Z, et al. Value of (18F)FDG PET radiomic features and VEGF expression in predicting pelvic lymphatic metastasis and their potential relationship in early-stage cervical squamous cell carcinoma. *Eur J Radiol*. 2018;106:160–6. <https://doi.org/10.1016/j.ejrad.2018.07.024>.

17. Qu Y-J, Liu G-B, Shi H-S, et al. Preoperative CT findings of thymoma are correlated with postoperative Masaoka clinical stage. *Acad Radiol*. 2013;20(1):66–72. <https://doi.org/10.1016/j.acra.2012.08.002>.
18. Hwang EJ, Paek MY, Yoon SH, et al. Quantitative thoracic magnetic resonance criteria for the differentiation of cysts from solid masses in the anterior mediastinum. *Korean J Radiol*. 2019;20(5):854–61. <https://doi.org/10.3348/kjr.2018.0699>.
19. Abdel Razeq AA, Khairy M, Nada N. Diffusion-weighted MR imaging in thymic epithelial tumors: correlation with World Health Organization classification and clinical staging. *Radiology*. 2014;273:268–75. <https://doi.org/10.1148/radiol.14131643>.
20. Iannarelli A, Sacconi B, Tomei F, et al. Analysis of CT features and quantitative texture analysis in patients with thymic tumors: correlation with grading and staging. *Radiol Med (Torino)*. 2018;123(5):345–50. <https://doi.org/10.1007/s11547-017-0845-4>.
21. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *EJC*. 2009;45:228–47.
22. Del Vecchio BG, Coppola M, Mannisi E, et al. Impact of endoscopic ultrasound-guided fine-needle aspiration and multidisciplinary approach in the management of abdominal or mediastinal mass. *Eur J Gastroenterol Hepatol*. 2015;27(9):1045–51. <https://doi.org/10.1097/MEG.0000000000000390>.
23. Han C, Lin R, Zhang Q, et al. Role of endoscopic ultrasound-guided fine needle aspiration in the diagnosis of mass lesions. *Exp Ther Med*. 2016;12(2):1085–92. <https://doi.org/10.3892/etm.2016.3433>.
24. Yasaka K, Akai H, Nojima M, et al. Quantitative computed tomography texture analysis for estimating histological subtypes of thymic epithelial tumors. *Eur J Radiol*. 2017;92:84–92. <https://doi.org/10.1016/j.ejrad.2017.04.017>.
25. Yasaka K, Akai H, Abe O, et al. Quantitative computed tomography texture analyses for anterior mediastinal masses: differentiation between solid masses and cysts. *Eur J Radiol*. 2018;100:85–91. <https://doi.org/10.1016/j.ejrad.2018.01.017>.
26. Wang X, Sun W, Liang H, et al. Radiomics signatures of computed tomography imaging for predicting risk categorization and clinical stage of thymomas. *Biomed Res Int*. 2019;201:3616852. <https://doi.org/10.1155/2019/3616852>.
27. Sui He, Liu L, Li X, et al. CT-based radiomics features analysis for predicting the risk of anterior mediastinal lesions. *J Thorac Dis*. 2019;11(5):1129–35.
28. Parmar C, Grossmann P, Bussink J, et al. Machine learning methods for quantitative radiomic biomarkers. *Sci Rep*. 2015;5:13087. <https://doi.org/10.1038/srep13087>.
29. Castellano G, Bonilha L, Li LM, et al. Texture analysis of medical images. *Clin Radiol*. 2004;59(12):1061–9. <https://doi.org/10.1016/j.crad.2004.07.008>.
30. Yu H, Buch K, Li B, et al. Utility of texture analysis for quantifying hepatic fibrosis on proton density MRI. *J Magn Reson Imaging*. 2015;42(5):1259–65. <https://doi.org/10.1002/jmri.24898>.
31. Zhonggao J, YiJiao W, Yongfeng W, et al. Multislice computed tomography performance in differential diagnosis of high-density thymic cyst and thymoma in lesions less than 3 cm. *Thorac Cancer*. 2018;9(10):1300–4. <https://doi.org/10.1111/1759-7714.12840>.
32. Shao Y, Pang P, et al. Predicts development of normal appearing white matter on conventional MR FLAIR images with Radiomics in the aging brain: a longitudinal clinical study. *Front Aging Neurosci*. 2018. <https://doi.org/10.3389/fnagi.2018.00393>.
33. Amadasun M, King R. Textural features corresponding to textural properties. *IEEE Trans Syst Man Cybern*. 1989;19:1264–74.
34. Boccino C, Carabellese A, Caruso T, et al. Use of gray value distribution of run length for texture analysis. *Pattern Recognit Lett*. 1990;11:415–9.
35. Lei Xu, Niu T, et al. A radiomics approach based on support vector machine using MR images for preoperative lymph node status evaluation in intrahepatic cholangiocarcinoma. *Theranostics*. 2019;9(18):5374–85.
36. Shu Z, Gong X, et al. Radiomics nomogram based on MRI for predicting white matter hyperintensity progression in elderly adults. *J Magn Reson Imaging*. 2020;51(2):535–46. <https://doi.org/10.1002/jmri.26813>.
37. Wu J, Aguilera T, et al. Early-stage non-small cell lung cancer: quantitative imaging characteristics of 18F fluorodeoxyglucose PET/CT allow prediction of distant metastasis. *Radiology*. 2016;281:270–8.
38. Mukaka MM. Statistic corner: A guide to appropriate use of correlation coefficient in medical research. *Malawi Med J*. 2012;24:69–71.
39. Dagher-Wojtkowiak E, Wiczling P, Bocian S, et al. Least absolute shrinkage and selection operator and dimensionality reduction techniques in quantitative structure retention relationship modeling of retention in hydrophilic interaction liquid chromatography. *J Chromatogr A*. 2015;17(7):54–62. <https://doi.org/10.1016/j.chroma.2015.05.025>.
40. Wu Y, Pan WB, et al. Survival Prediction in high-grade osteosarcoma using radiomics of diagnostic computed tomography. *EBipMedicine*. 2018;34:27–34.
41. O'Brien RM. A caution regarding rules of thumb for variance inflation factors. *Qual Quant*. 2007;41:673–90.
42. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. *Evolution*. 1985;39:783–91.
43. Kramer AA, Zimmerman JE. Assessing the calibration of mortality benchmarks in critical care: the Hosmer–Lemeshow test revisited. *Crit Care Med*. 2007;35:2052–6.
44. Xu L, Yang PF, Niu TY, et al. A radiomics approach based on support vector machine using MR images for preoperative lymph node status evaluation in intrahepatic cholangiocarcinoma. *Theranostics*. 2019;9(18):5374–85. <https://doi.org/10.7150/thno.34149>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.